G92.03 Immune effector cell-associated neurotoxicity syndrome, grade 3

Name of the Condition

• Immune effector cell-associated neurotoxicity syndrome, grade 3

Summary

Immune effector cell-associated neurotoxicity syndrome (ICANS) is a neurological condition that can occur following treatment with certain immunotherapies, particularly those involving immune effector cells like CAR T-cells. It is characterized by a range of neurologic symptoms resulting from inflammation or toxicity to the central nervous system. The "grade 3" designation indicates severe severity, typically involving significant impairment that requires medical intervention.

Causes

ICANS is caused by the release of inflammatory cytokines and immune-mediated damage to the brain and nervous system, typically triggered by immunotherapy treatments that activate immune cells to target cancer cells. The exact mechanisms involve cytokine release and potential direct neurotoxic effects.

Risk Factors

• Receipt of immunotherapy, especially CAR T-cell therapy or other immune effector cell treatments
• Underlying cancer type and disease burden
• Prior history of neurologic conditions or central nervous system involvement
• Concomitant use of other medications that may affect neurologic function

Symptoms

• Altered mental status or confusion
• Aphasia (difficulty speaking or understanding language)
• Tremors or asterixis (hand flapping)
• Seizures
• Headache
• Dizziness or ataxia (loss of coordination)
• Visual disturbances

Diagnosis

Diagnosis is based on clinical evaluation of neurologic symptoms, often supported by imaging or laboratory tests to rule out other causes. Severity grading follows standardized criteria, with grade 3 indicating significant impairment requiring intervention.

Treatment Options

Treatment focuses on managing symptoms and reducing inflammation, which may include corticosteroids, antiseizure medications, or other supportive care. Immunotherapy may be paused or adjusted based on severity.

Prognosis and Follow-Up

Prognosis depends on the severity of symptoms and response to treatment. Close monitoring is essential, with follow-up to assess recovery and manage long-term effects.

Complications

Severe cases may lead to prolonged neurologic impairment, seizures, or other serious complications requiring intensive care.

Lifestyle & Prevention

Prevention involves careful patient selection and monitoring during immunotherapy. Lifestyle modifications are not typically applicable, but adherence to treatment protocols is critical.

When to Seek Professional Help

Seek immediate medical attention if symptoms worsen or new neurologic symptoms develop, as grade 3 ICANS requires prompt intervention.

Tips for Medical Coders

Code G92.03 is used for immune effector cell-associated neurotoxicity syndrome, grade 3. Documentation should specify the severity grade and associated clinical findings to support accurate coding.